Case Report| Volume 24, ISSUE 2, e55-e59, March 2023

Pregnancy and Pathways to Motherhood in Oncogene-driven Lung Cancer: A Single Institution Experience

Published:November 10, 2022DOI:

      Clinical Practice Points

      • Limited case report data are available describing pregnancy and motherhood in oncogene-driven non-small cell lung cancer (NSCLC), which is likely to become more common as survival for advanced oncogene-driven NSCLC increases. We found that 50/55 of the women of child-bearing age treated at our institution for NSCLC over 2010 to 2021 had an oncogene driver. Nine of 55 (16%) were diagnosed during or within a year of pregnancy. Similar to prior reports, in our series, early pregnancies at or after diagnosis were terminated and a later pregnancy was delivered preterm to avoid fetal exposure to targeted therapy. Six of 55 women pursued having a child after initiating treatment with targeted therapy, of which two were successful via adoption and one was successful via gestational surrogate. Gestational surrogacy and adoption are thus feasible for women with oncogene-driven NSCLC. Effects of targeted therapies on pregnancy remain understudied. Patients and providers are encouraged to register cases of pregnancy in cancer in one of two available registries, either via an institution affiliated with the International Network of Cancer, Infertility and Pregnancy (see or direct patient contact with the Cancer and Pregnancy registry at


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Clinical Lung Cancer
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Vinolas N
        • Garrido P
        • Isla D
        • et al.
        Lung cancer in never-smoking women: a sub-analysis of the Spanish female-specific database WORLD07.
        Cancer Invest. 2017; 35: 358-365
        • Cho J
        • Choi SM
        • Lee J
        • et al.
        Proportion and clinical features of never-smokers with non-small cell lung cancer.
        Chin J Cancer. 2017; 36: 20
        • Hirsch FR
        • Suda K
        • Wiens J
        • Bunn Jr., PA
        New and emerging targeted treatments in advanced non-small-cell lung cancer.
        Lancet. 2016; 388: 1012-1024
        • Passaro A
        • Attili I
        • Rappa A
        • et al.
        Genomic Characterization of Concurrent Alterations in Non-Small Cell Lung Cancer (NSCLC) harboring actionable mutations.
        Cancers (Basel). 2021; 13
        • Dagogo-Jack I
        • Gainor JF
        • Porter RL
        • et al.
        Clinicopathologic features of NSCLC diagnosed during pregnancy or the peripartum period in the era of molecular genotyping.
        J Thorac Oncol. 2016; 11: 1522-1528
        • Yang L
        • He YT
        • Kang J
        • et al.
        Clinical features and intervention timing in patients with pregnancy-associated non-small-cell lung cancer.
        J Thorac Dis. 2021; 13: 4125-4136
        • Tarigopula A
        • Ramasubban G
        • Chandrashekar V
        • Govindasami P
        • Chandran C.
        EGFR mutations and ROS1 and ALK rearrangements in a large series of non-small cell lung cancer in South India.
        Cancer Rep (Hoboken). 2020; 3: e1288
        • Shaw AT
        • Yeap BY
        • Mino-Kenudson M
        • et al.
        Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK.
        J Clin Oncol. 2009; 27: 4247-4253
        • Su HI
        • Connell MW
        • Bazhenova LA.
        Ovarian stimulation in young adult cancer survivors on targeted cancer therapies.
        Fertil Steril. 2016; 106: 1475-1478
        • Gillis R
        • Meirovitz M
        • Ben David Hadani M
        • Hourvitz A
        • Peled N
        Is ALK inhibitor a contraindication for subsequent IVF pregnancy?.
        J Thorac Oncol. 2019; 14: e176-e178
        • Connor L.
        Mum battling incurable lung cancer stuns doctors and welcomes 'impossible' baby girl.
        Mirror. 2021; : 2021
        • Scarfone G
        • Fumagalli M
        • Imbimbo M
        • et al.
        First case report of pregnancy on Alectinib in a woman with metastatic alk-rearranged lung cancer: a case report.
        J Thorac Oncol. 2021; 16: 873-877
        • Rivas G
        • Llinas N
        • Bonilla C
        • Rubiano J
        • Cuello J
        • Arango N.
        Use of erlotinib throughout pregnancy: a case-report of a patient with metastatic lung adenocarcinoma.
        Lung Cancer. 2012; 7: 469-472
        • Ji Y
        • Schwartz J
        • Hartford A
        • Ramsey J
        • Phillips J
        • Verschraegen C.
        Successful Treatment of Non-Small Cell Lung Cancer With Erlotinib Throughout Pregnancy.
        JAMA Oncol. 2015; 1: 838-840
        • Zambelli A
        • Prada GA
        • Fregoni V
        • Ponchio L
        • Sagrada P
        • Pavesi L.
        Erlotinib administration for advanced non-small cell lung cancer during the first 2 months of unrecognized pregnancy.
        Lung Cancer. 2008; 60: 455-457
        • Seager M
        • Aisner DL
        • Davies KD.
        Oncogenic gene fusion detection using anchored multiplex polymerase chain reaction followed by next generation sequencing.
        J Vis Exp. 2019; 149
        • Maggen C
        • Wolters V
        • Cardonick E
        • et al.
        Pregnancy and cancer: the INCIP Project.
        Curr Oncol Rep. 2020; 22: 17
        • Cardonick E
        • Seidman L.
        Meeting the proposal for service improvement for pregnant women with cancer.
        Breast. 2022; 64: 159